Share This Article:

Plants: The Future Pharmaceutical Factory

Abstract Full-Text HTML XML Download Download as PDF (Size:151KB) PP. 319-327
DOI: 10.4236/ajps.2014.53044    5,901 Downloads   8,593 Views   Citations

ABSTRACT

The main objective of this study was to identify prospects, advantages and challenges of plant molecular farming. Plant-made pharmaceuticals (PMPs) and plant made vaccines (PMVs) were intended to be used for human consumption. A broad range of plants, including crops, vegetables and fruits have been investigated for their applicability in production of pharmaceuticals over the last two decades. At present, mainly maize, rice, tobacco and safflower are used in open field production. Contained bioreactor-type systems focus on moss, algae and plant organ culture. Expression systems include stable transformation of plant genomesboth nuclear and plastid, which are also used in the generation of genetically modified crops, plant-viruses and transient expressions. Each expression system (production platform) offers different advantages and disadvantages. Production platform choice is perceptive and depends on a broad range of criterion. This study is based on literature reviews, document analysis and internet database browsing.


Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

B. Sil and S. Jha, "Plants: The Future Pharmaceutical Factory," American Journal of Plant Sciences, Vol. 5 No. 3, 2014, pp. 319-327. doi: 10.4236/ajps.2014.53044.

References

[1] Biotechnology Industry Organization (BIO), 2011.
http://www.bio.org/search/node/plantmadepharmaceuticals
[2] J. K. Ma, P. M. Drake and P. Christou, “The Production of Recombinant Pharmaceutical Proteins in Plants,” Nature Reviews Genetics, Vol. 4, No. 10, 2003, pp. 794-805.
http://dx.doi.org/10.1038/nrg1177
[3] O. O. Obembe, J. O. Popoola, S. Leelavathi and S. V. Reddy, “Advances in Plant Molecular Farming,” Biotechnology Advances, Vol. 29, No. 2, 2011, pp. 210-222.
http://dx.doi.org/10.1016/j.biotechadv.2010.11.004
[4] R. Fischer, E. Stoger, S. Schillberg and P. Christou, “Plant-Based Production of Biopharmaceuticals,” Current Opinion in Plant Biology, Vol. 7, No. 2, 2004, pp. 152-158.
http://dx.doi.org/10.1016/j.pbi.2004.01.007
[5] A. Spök, R. M. Twyman, R. Fischer and J. K. Ma, “Evolution of a Regulatory Framework for Pharmaceuticals Derived from Genetically Modified Plants,” Trends in Biotechnology, Vol. 26, No. 9, 2008, pp. 506-517.
http://dx.doi.org/10.1016/j.tibtech.2008.05.007
[6] H. Daniell, S. J. Streatfield and K. Wycoff, “Medical Molecular Farming: Production of Antibodies, Biopharmaceuticals and Edible Vaccines in Plants,” Trends in Plant Science, Vol. 6, No. 5, 2001, pp. 219-226.
http://dx.doi.org/10.1016/S1360-1385(01)01922-7
[7] S. J. Streatfield, “Approaches to Achieve High-Level Heterologous Protein Production in Plants,” Plant Biotechnology Journal, Vol. 5, No. 1, 2007, pp. 2-15.
http://dx.doi.org/10.1111/j.1467-7652.2006.00216.x
[8] T. Kawakatsu and F. Takaiwa, “Cereal Seed Storage Protein Synthesis: Fundamental Processes for Recombinant Protein Production in Cereal Grains,” Plant Biotechnology Journal, Vol. 8, No. 9, 2010, pp. 939-953.
http://dx.doi.org/10.1111/j.1467-7652.2010.00559.x
[9] A. L. Demain and P. Vaishnav, “Production of Recombinant Proteins by Microbes and Higher Organisms,” Biotechnology Advances, Vol. 27, No. 3, 2009, pp. 297-306.
http://dx.doi.org/10.1016/j.biotechadv.2009.01.008
[10] D. V. Goeddel, D. G. Kleid, F. Bolivar and H. L. Heyneker, “Expression in Escherichia coli of Chemically Synthesized Genes for Human Insulin,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 76, No. 1, 1979, pp. 106-110.
http://dx.doi.org/10.1073/pnas.76.1.106
[11] S. R. Karg and P. T. Kallio, “The Production of Biopharmaceuticals in Plant Systems,” Biotechnology Advances, Vol. 27, No. 6, 2009, pp. 879-894.
http://dx.doi.org/10.1016/j.biotechadv.2009.07.002
[12] J. Boothe, C. Nykiforuk, Y. Shen and S. Zaplachinski, “Seed-Based Expression Systems for Plant Molecular Farming,” Plant Biotechnology Journal, Vol. 8, No. 5, 2010, pp. 588-606.
http://dx.doi.org/10.1111/j.1467-7652.2010.00511.x
[13] V. Gomord, A. C. Fitchette, L. Menu-Bouaouiche and C. Saint-Jore-Dupas, “Plant-Specific Glycosylation Patterns in the Context of Therapeutic Protein Production,” Plant Biotechnology Journal, Vol. 8, No. 5, 2010, pp. 564-587.
http://dx.doi.org/10.1111/j.1467-7652.2009.00497.x
[14] L. M. Houdebine, “Production of Pharmaceutical Proteins by Transgenic Animals,” Comparative Immunology, Microbiology and Infectious Diseases, Vol. 32, No. 2, 2009, pp. 107-121.
http://dx.doi.org/10.1016/j.cimid.2007.11.005
[15] J. W. Larrick and D. W. Thomas, “Producing Proteins in Transgenic Plants and Animals,” Current Opinion in Biotechnology, Vol. 12, No. 4, 2001, pp. 411-418.
http://dx.doi.org/10.1016/S0958-1669(00)00236-6
[16] D. Salamone, L. Baranao, C. Santos and L. Bussmann “High Level Expression of Bioactive Recombinant Human Growth Hormone in the Milk of a Cloned Transgenic Cow,” Journal of Biotechnology, Vol. 124, No. 2, 2006, pp. 469-472.
http://dx.doi.org/10.1016/j.jbiotec.2006.01.005
[17] G. R. Vianna, N. B. Cunha, A. M. Murad and E. L. Rech “Soybeans as Bioreactors for Biopharmaceuticals and Industrial Proteins,” Genetics and Molecular Research, Vol. 10, No. 3, 2011, pp. 1733-1752.
http://dx.doi.org/10.4238/vol10-3gmr1476
[18] R. Tremblay, D. Wang, A. M. Jevnikar and S. Ma, “Tobacco, a Highly Efficient Green Bioreactor for Production of Therapeutic Proteins,” Biotechnology Advances, Vol. 28, No. 2, 2010, pp. 214-221.
http://dx.doi.org/10.1016/j.biotechadv.2009.11.008
[19] V. Gomord, C. Sourrouille, A. C. Fitchette and M. Bardor, “Production and Glycosylation of Plant-Made Pharmaceuticals: The Antibodies as a Challenge,” Plant Biotechnology Journal, Vol. 2, No. 2, 2004, pp. 83-100.
http://dx.doi.org/10.1111/j.1467-7652.2004.00062.x
[20] D. Lienard, C. Sourrouille, V. Gomord and L. Faye, “Pharming and Transgenic Plants,” Biotechnology Annual Review, Vol. 13, 2007, pp. 115-147.
http://dx.doi.org/10.1016/S1387-2656(07)13006-4
[21] V. Gomord and L. Faye, “Posttranslational Modification of Therapeutic Proteins in Plants,” Current Opinion in Plant Biology, Vol. 7, No. 2, 2004, pp. 171-181.
http://dx.doi.org/10.1016/j.pbi.2004.01.015
[22] N. Sethuraman and T. A. Stadheim, “Challenges in Therapeutic Glycoprotein Production,” Current Opinion in Biotechnology, Vol. 17, No. 4, 2006, pp. 341-346.
http://dx.doi.org/10.1016/j.copbio.2006.06.010
[23] G. Graef, B. J. LaVallee, P. Tenopir and M. Tat, “A High-Oleic-Acid and Low-Palmitic-Acid Soybean: Agronomic Performance and Evaluation as a Feedstock for Biodiesel,” Plant Biotechnology Journal, Vol. 7, No. 5, 2009, pp. 411-421.
http://dx.doi.org/10.1111/j.1467-7652.2009.00408.x
[24] J. Xu, X. Ge and M. C. Dolan, “Towards High-Yield Production of Pharmaceutical Proteins with Plant Cell Suspension Cultures,” Biotechnology Advances, Vol. 29, No. 3, 2011, pp. 278-299.
http://dx.doi.org/10.1016/j.biotechadv.2011.01.002
[25] Y. Gleba, V. Klimyuk and S. Marillonnet, “Magnifection—A New Platform for Expressing Recombinant Vaccines in Plants,” Vaccine, Vol. 23, No. 17-18, 2005, pp. 2042-2048. http://dx.doi.org/10.1016/j.vaccine.2005.01.006
[26] E. Stoger, J. K. Ma, R. Fischer and P. Christou, “Sowing the Seeds of Success: Pharmaceutical Proteins from Plants,” Current Opinion in Biotechnology, Vol. 16, No. 2, 2005, pp. 167-173.
http://dx.doi.org/10.1016/j.copbio.2005.01.005
[27] D. Lee and E. Natesan, “Evaluating Genetic Containment Strategies for Transgenic Plants,” Trends in Biotechnology, Vol. 24, No. 3, 2006, pp. 109-114.
http://dx.doi.org/10.1016/j.tibtech.2006.01.006

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.